Indication:
Sevelamer Carbonate Tablets is indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.  
Strength:0.8g/Tablet
Innovator: Genzyme Europe B.V./Sanofi B.V.
Innovative Brand: Renvela/Renagel
Has passed Consistency Evaluation
（2020.07）
Qualification: Approved in China and the exported regions. Exporting to CIS/Southeast Asia
Key selling points: 
1. First Generic Drug Approved in China.
2. As a Highly cross-linked polymers, Sevelamer Carbonate Tablets is insoluble and non-absorbable in the digestive tract, minimizing systemic side effects. 
3. Compared to traditional phosphorus binders, Sevelamer Carbonate Tablets are devoid of metal and calcium components, thereby preventing potential issues of metal accumulation or calcium overload with prolonged use.